HCC70-luc Orthotopic Mouse Model Service for Breast Cancer

The HCC70-luc orthotopic mouse model stands as a powerful preclinical platform for interrogating triple-negative breast cancer biology and evaluating novel therapeutic candidates in an anatomically relevant setting. Alfa Cytology builds and validates HCC70-luc orthotopic xenografts with stringent quality controls, offering researchers a dependable, imaging-enabled system to accelerate their TNBC drug discovery and development programs from early efficacy screening through mechanistic validation.

Overview of HCC70-luc Orthotopic Mouse Model for Breast Cancer

HCC70 is a human breast cancer cell line originally isolated from a primary ductal carcinoma resected from a 49-year-old patient, classified pathologically as stage IIIA, grade 3 invasive ductal carcinoma with metastatic involvement in regional lymph nodes. Molecularly, HCC70 is defined by the triple-negative phenotype—negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 overexpression—combined with mutant TP53 and a basal-like 2 (BL2) transcriptional signature. This molecular profile confers an aggressive, highly proliferative behavior that closely mirrors the clinical challenge of treating triple-negative breast cancer, a subtype notorious for its lack of approved targeted therapies and its propensity for early relapse. The HCC70-luc derivative incorporates a constitutively expressed firefly luciferase reporter, enabling sensitive, whole-body optical tracking of tumor establishment, local progression, and metastatic seeding through non-invasive bioluminescence imaging. When introduced orthotopically into the mammary fat pad of immunodeficient mice, HCC70-luc tumors grow with reliable kinetics and maintain the basal-like histopathology and therapeutic sensitivity patterns characteristic of human TNBC.

Fig 1. Immunofluorescence of HCC70 cell clusters, detection of primary tumor growth and lung metastasis in orthotopically transplanted NSG mice. (Wrenn, Emma D., et al., 2020)

The orthotopic implantation strategy is particularly valuable for HCC70-luc because it recreates the tumor–stroma interactions, hypoxic gradients, and extracellular matrix architecture that drive basal-like breast cancer progression in patients. Unlike subcutaneous models, the mammary fat pad microenvironment supports physiologically relevant angiogenesis, nutrient diffusion, and immune cell infiltration patterns—factors that significantly modulate drug penetration and anti-tumor response. The addition of luciferase imaging further elevates the model's translational utility by allowing quantitative, longitudinal readouts of tumor burden without the need for serial sacrifice, thereby reducing animal usage while increasing statistical power. This combination of molecular fidelity, anatomical relevance, and non-invasive monitoring makes the HCC70-luc orthotopic model an essential tool for preclinical TNBC research, from cytotoxic chemotherapy benchmarking to the evaluation of emerging targeted agents and immunotherapy combinations.

Cell Line Information: HCC70-luc

HCC70-luc is a luciferase-tagged derivative of the parental HCC70 human breast adenocarcinoma cell line, generated via stable transduction with a firefly luciferase expression cassette under a constitutive promoter. The parental line was established in 1992 from a primary invasive ductal carcinoma and took 44 months to achieve stable culture. HCC70 is classified within the basal-like 2 (BL2) molecular subtype of triple-negative breast cancer, a classification that remains stable across in vitro culture and in vivo xenograft settings. The luciferase-expressing variant preserves the parental line's triple-negative status, p53 overexpression, and aggressive growth characteristics while enabling real-time optical quantification of tumor dynamics. The table below outlines the defining attributes of the HCC70-luc cell line as utilized in orthotopic xenograft construction.

Our Services

Alfa Cytology delivers comprehensive HCC70-luc orthotopic model services that span authenticated cell line expansion, precision surgical implantation into the mammary fat pad, serial bioluminescence imaging, and multi-modal endpoint characterization encompassing histopathology, immunohistochemistry, and molecular profiling. Our in vivo oncology group operates under fully reviewed IACUC protocols with meticulous documentation aligned to GLP standards, ensuring that each study yields robust, audit-ready data to advance your TNBC therapeutic pipeline from lead compound evaluation through IND-enabling studies.

Workflow of HCC70-luc Orthotopic Mouse Model Construction

Construction of the HCC70-luc orthotopic breast cancer model follows a streamlined yet rigorous protocol designed to achieve consistent tumor engraftment, minimize surgical morbidity, and enable quantitative longitudinal imaging. The entire procedure typically spans five to eight weeks from cell preparation through final endpoint analysis, with quality assurance integrated at each critical juncture.

1. Cell Line Authentication and Expansion: HCC70-luc cells are revived from authenticated cryogenic master stocks and expanded in antibiotic-free RPMI 1640 complete medium for a minimum of two passages prior to inoculation. STR profiling confirms cell identity against the reference database, while in vitro luciferase assay verifies reporter expression stability. Mycoplasma testing and viability assessment (>95% by trypan blue exclusion) are completed immediately before harvest.
2. Cell Harvest and Preparation for Implantation: Sub-confluent cultures are dissociated with trypsin-EDTA, washed twice in sterile PBS, and enumerated by automated cell counter. The cell pellet is resuspended in ice-cold PBS or serum-free medium at the target concentration. Where study design specifies, cells are combined 1:1 with reduced-growth-factor Matrigel to enhance engraftment efficiency in the immunodeficient host.
3. Surgical Implantation into the Mammary Fat Pad: Female Nu/Nu or NSG mice aged 6–10 weeks are anesthetized with 2–3% isoflurane in oxygen. The right inguinal mammary fat pad (#4) is exposed through a small skin incision, gently exteriorized, and stabilized. A 27-gauge syringe is used to inject 25–50 µl of cell suspension (typically 5 × 10⁶ to 1 × 10⁷ cells) into the central stromal region. The needle is held in place for 10 seconds to prevent reflux, the fat pad is returned to position, and the skin is closed with surgical staples or tissue adhesive.
4. Post-Operative Monitoring and Recovery: Mice are transferred to a warmed recovery chamber and observed until fully ambulatory. Post-operative analgesia (buprenorphine 0.05–0.1 mg/kg subcutaneously) is administered every 8–12 hours for 48 hours. Body weight, food intake, wound integrity, and activity are monitored daily for the first week and twice weekly thereafter. Humane endpoint criteria are applied to any animal showing >15% body weight loss or signs of distress.
5. Baseline and Longitudinal Bioluminescence Imaging: Between days 3 and 7 post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg in 200 µl PBS) and are imaged under maintenance isoflurane anesthesia using an IVIS Spectrum or equivalent optical platform. Standardized acquisition parameters are locked for the study duration. Photon flux within a region of interest over the mammary fat pad confirms engraftment and establishes baseline tumor burden. Imaging is repeated at regular intervals (every 4–7 days) to track tumor growth longitudinally.
6. Tumor Volume Measurement and Growth Curve Generation: Tumor dimensions are measured twice weekly with digital calipers, and volume is calculated as V = (length × width²) / 2. Caliper-derived volumes and BLI photon flux values are plotted longitudinally for individual animals and cohorts, enabling early detection of therapeutic response divergence and informing dosing schedule adjustments.
7. Study Endpoint and Comprehensive Necropsy: When tumors reach approximately 400–1,000 mm³ or a predetermined timepoint (typically day 21–35), mice are humanely euthanized. A full necropsy is performed with collection of the residual mammary fat pad, regional lymph nodes, lungs, liver, and other tissues as specified. Specimens are subjected to ex vivo bioluminescence confirmation, formalin-fixed paraffin-embedded histopathology (H&E), immunohistochemistry (Ki-67, cleaved caspase-3, E-cadherin), and molecular analyses (Western blot, qPCR, RNA-seq) aligned with study objectives.

Fig 2. HCC70-luc Orthotopic Mouse Model construction workflow.

Case Study-HCC70-luc Orthotopic Mouse Model Development

In a recent preclinical engagement, Alfa Cytology leveraged the HCC70-luc orthotopic platform to evaluate the efficacy of a novel poly(ADP-ribose) polymerase (PARP) inhibitor in combination with a platinum-based DNA-damaging agent against triple-negative breast cancer. Following orthotopic implantation of 5 × 10⁶ HCC70-luc cells into Nu/Nu mice, tumors were permitted to establish for 14 days prior to randomization into vehicle, monotherapy, and combination treatment groups. Serial bioluminescence imaging conducted at weekly intervals demonstrated that the combination regimen produced a pronounced and sustained reduction in tumor photon flux relative to either single-agent arm, with statistically significant separation emerging by the third week of treatment. At study endpoint, combination-treated animals exhibited markedly lower final tumor volumes, reduced Ki-67 proliferation indices, and elevated levels of γH2AX indicative of enhanced DNA damage, supporting the mechanistic rationale for PARP inhibitor–platinum synergy in TNBC. These findings highlight the capacity of the HCC70-luc orthotopic model to generate quantitative efficacy and pharmacodynamic data for combination therapeutic strategies in the triple-negative breast cancer space.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your partner for HCC70-luc orthotopic studies means accessing a unified preclinical service ecosystem where cell line integrity, surgical expertise, advanced imaging, and analytical depth are managed under one quality framework. We are dedicated to producing data packages that meet the exacting standards of both peer-reviewed journals and regulatory agencies.

• Our HCC70-luc master cell banks undergo rigorous STR authentication, mycoplasma clearance, and luciferase expression stability validation to ensure consistent engraftment and imaging performance across every study.
• We possess demonstrated surgical proficiency in mammary fat pad orthotopic implantation within immunodeficient strains, achieving reliable tumor take rates with minimal perioperative complications under accredited IACUC oversight.
• On-site IVIS bioluminescence imaging infrastructure enables rapid acquisition of quantitative tumor burden data, with calibrated ROI analysis and longitudinal photon flux trending delivered in publication-ready formats.
• Our adaptable study designs accommodate various treatment paradigms—including single-agent, combination, and dose-escalation arms—tailored to the pharmacological characteristics of your investigational compounds.
• Integrated endpoint capabilities span histopathology, IHC, digital image analysis, and biomarker quantification, eliminating the logistical complexity of coordinating multiple external service providers.
• All protocols are executed with comprehensive GLP-aligned documentation, chain-of-custody records, and raw data archival to support IND submissions, investor presentations, and manuscript preparation.
• Our Ph.D.-level scientific directors bring specialized expertise in TNBC biology, DNA damage response pathways, and targeted therapy pharmacology, remaining actively engaged in protocol design, interim analysis, and report generation throughout your project.

Contact Us

If your research program requires a validated triple-negative breast cancer model with quantitative bioluminescence readouts and comprehensive endpoint characterization, we welcome you to reach out to us to discuss how Alfa Cytology can tailor an HCC70-luc orthotopic study to your compound, target, and milestone needs. Contact us today to arrange a consultation with our scientific team and receive a detailed project proposal.

For research use only. Not intended for any clinical use.